As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2025. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare. 

To view the full report, download the PDF at the top of this page. Additionally, an Excel list of relevant upcoming catalysts for these drugs can be downloaded under the support material. 

Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com. 

For our disclosures, please read the Biomedtracker Research Standards.